no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
1 |
Abstracts
|
|
|
2010 |
19 |
4 |
p. 496-546 |
article |
2 |
Antiphospholipid antibodies and the protein C pathway
|
Urbanus, RT |
|
2010 |
19 |
4 |
p. 394-399 |
article |
3 |
Anti-phospholipid antibody mediated fetal loss: still an open question from a pathogenic point of view
|
Meroni, PL |
|
2010 |
19 |
4 |
p. 453-456 |
article |
4 |
Antiphospholipid antibody profile: implications for the evaluation and management of patients
|
Tincani, A. |
|
2010 |
19 |
4 |
p. 432-435 |
article |
5 |
Antiphospholipid syndrome and the brain in pediatric and adult patients
|
Muscal, E. |
|
2010 |
19 |
4 |
p. 406-411 |
article |
6 |
Antiphospholipid syndrome: critical analysis of the diagnostic path
|
Pengo, V. |
|
2010 |
19 |
4 |
p. 428-431 |
article |
7 |
Antiphospholipid syndrome (Hughes syndrome): 10 clinical topics
|
Hughes, GRV |
|
2010 |
19 |
4 |
p. 343-346 |
article |
8 |
Antiphospholipid syndrome treatment beyond anticoagulation: are we there yet?
|
Pierangeli, SS |
|
2010 |
19 |
4 |
p. 475-485 |
article |
9 |
Antiprothrombin antibody: why do we need more assays?
|
Atsumi, T. |
|
2010 |
19 |
4 |
p. 436-439 |
article |
10 |
Antithrombotic treatment failures in antiphospholipid syndrome: the new anticoagulants?
|
Cohen, H. |
|
2010 |
19 |
4 |
p. 486-491 |
article |
11 |
Authors Index
|
|
|
2010 |
19 |
4 |
p. 547-550 |
article |
12 |
Autoimmunity, infection and adjuvants
|
Rose, NR |
|
2010 |
19 |
4 |
p. 354-358 |
article |
13 |
Catastrophic antiphospholipid syndrome (CAPS): update from the ‘CAPS Registry’
|
Cervera, R. |
|
2010 |
19 |
4 |
p. 412-418 |
article |
14 |
Domain I of β2-glycoprotein I: its role as an epitope and the potential to be developed as a specific target for the treatment of the antiphospholipid syndrome
|
Ioannou, Y. |
|
2010 |
19 |
4 |
p. 400-405 |
article |
15 |
Non-criteria manifestations of antiphospholipid syndrome
|
Erkan, D. |
|
2010 |
19 |
4 |
p. 424-427 |
article |
16 |
Obstetric antiphospholipid syndrome: current uncertainties should guide our way
|
Branch, DW |
|
2010 |
19 |
4 |
p. 446-452 |
article |
17 |
Obstetric antiphospholipid syndrome: still a challenge
|
Levy, RA |
|
2010 |
19 |
4 |
p. 457-459 |
article |
18 |
Pathophysiology of β2-glycoprotein I in antiphospholipid syndrome
|
Matsuura, E. |
|
2010 |
19 |
4 |
p. 379-384 |
article |
19 |
Proteomics in antiphospholipid syndrome: a review
|
Cuadrado, MJ |
|
2010 |
19 |
4 |
p. 385-388 |
article |
20 |
Risky business: the interpretation, use, and abuse of antiphospholipid antibody tests in clinical practice
|
Roubey, RAS |
|
2010 |
19 |
4 |
p. 440-445 |
article |
21 |
Role of tissue factor in thrombosis in antiphospholipid antibody syndrome
|
Boles, J. |
|
2010 |
19 |
4 |
p. 370-378 |
article |
22 |
Some antiphospholipid antibodies bind to various serine proteases in hemostasis and tip the balance toward hypercoagulant states
|
Chen, PP |
|
2010 |
19 |
4 |
p. 365-369 |
article |
23 |
Speakers Abstracts
|
|
|
2010 |
19 |
4 |
p. 492-495 |
article |
24 |
The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis
|
Rand, JH |
|
2010 |
19 |
4 |
p. 460-469 |
article |
25 |
The dual role of innate immunity in the antiphospholipid syndrome
|
Rauch, J. |
|
2010 |
19 |
4 |
p. 347-353 |
article |
26 |
The role of LRP8 (ApoER2’) in the pathophysiology of the antiphospholipid syndrome
|
de Groot, PG |
|
2010 |
19 |
4 |
p. 389-393 |
article |
27 |
Towards evidence-based treatment of thrombotic antiphospholipid syndrome
|
Derksen, Rhwm |
|
2010 |
19 |
4 |
p. 470-474 |
article |
28 |
Update on anti-phospholipid antibodies in SLE: the Hopkins’ Lupus Cohort
|
Petri, M. |
|
2010 |
19 |
4 |
p. 419-423 |
article |
29 |
Use of monoclonal antibodies to dissect specificity and pathogenesis of antiphospholipid antibodies
|
Lambrianides, A. |
|
2010 |
19 |
4 |
p. 359-364 |
article |